Cargando…

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal

Detalles Bibliográficos
Autores principales:	Novi, Giovanni, Ghezzi, Angelo, Pizzorno, Matteo, Lapucci, Caterina, Bandini, Fabio, Annovazzi, Pietro, Mancardi, Giovanni L., Uccelli, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532747/ https://www.ncbi.nlm.nih.gov/pubmed/28804745 http://dx.doi.org/10.1212/NXI.0000000000000377

Ejemplares similares

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
Publicado: (2018)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
por: Serpero, Laura D., et al.
Publicado: (2013)

Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS
por: Novi, Giovanni, et al.
Publicado: (2020)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
por: Mehling, Matthias, et al.
Publicado: (2014)

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
por: Koska, Valeria, et al.
Publicado: (2021)

Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder
por: Lin, Wei, et al.
Publicado: (2023)

Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS
por: Cellerino, Maria, et al.
Publicado: (2019)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy?
por: Oel, Dierk, et al.
Publicado: (2021)

Continuing fingolimod after development of macular edema: A case report
por: Li, Vivien, et al.
Publicado: (2014)

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Tailoring B cell depletion therapy in MS according to memory B cell monitoring
por: Novi, Giovanni, et al.
Publicado: (2020)

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
por: Barry, Brian, et al.
Publicado: (2019)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Severe rebound disease activity after fingolimod withdrawal in a pregnant woman with multiple sclerosis managed with rituximab: A case study
por: Canibaño, Beatriz, et al.
Publicado: (2019)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

Quantitative Assessment of Finger Motor Impairment in Multiple Sclerosis
por: Bonzano, Laura, et al.
Publicado: (2013)

Fingolimod: Rebound effect in the form of exacerbation of COVID-19: case report
Publicado: (2021)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Acute disseminated encephalomyelitis after SARS-CoV-2 infection
por: Novi, Giovanni, et al.
Publicado: (2020)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Pasteur Dramatized
por: Packard, Francis R.
Publicado: (1919)

Dramatic Response to Anti-IL-6 Receptor Therapy in Children With Life-Threatening Myelin Oligodendrocyte Glycoprotein-Associated Disease
por: McLendon, Loren A., et al.
Publicado: (2023)

CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis
por: Schiavetti, Irene, et al.
Publicado: (2023)

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
por: Naser Moghadasi, Abdoreza, et al.
Publicado: (2020)

Evaluation of the Rebound Hernia Repair Device for Laparoscopic Hernia Repair
por: Torres-Villalobos, Gonzalo, et al.
Publicado: (2010)

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
por: Novi, Giovanni, et al.
Publicado: (2020)

Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases
por: Schmidt, Stephan, et al.
Publicado: (2019)

Impact of treatment on cellular immunophenotype in MS: A cross-sectional study
por: Cellerino, Maria, et al.
Publicado: (2020)

Efficacy of anakinra on rebound of multisystem inflammatory syndrome
por: Brisca, Giacomo, et al.
Publicado: (2022)

Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19
por: Fuchs, Vidmante, et al.
Publicado: (2021)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

Narrative review based on fingolimod therapy in pediatric MS
por: Piri Cinar, Bilge, et al.
Publicado: (2023)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l2163anlgvdjql8fajg72rkcn9